Stelios Papadopoulos - May 16, 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
May 16, 2024
Transactions value $
$0
Form type
4
Date filed
5/17/2024, 04:38 PM
Previous filing
Mar 15, 2024
Next filing
May 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +30K $0.00 30K May 16, 2024 Common Stock 30K $2.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service.